Back to Search Start Over

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1.

Authors :
Zuo F
Sun R
Abolhassani H
Du L
Wang Y
Vlachiotis S
Bertoglio F
Schubert M
Rezaei N
Chavoshzadeh Z
Guerra C
Cavalli A
Andréll J
Kumagai-Braesch M
Xue Y
Cao Y
Hust M
Robbiani DF
Xie XS
Hammarström L
Marcotte H
Pan-Hammarström Q
Source :
The Lancet regional health. Western Pacific [Lancet Reg Health West Pac] 2023 Apr; Vol. 33, pp. 100762. Date of Electronic Publication: 2023 Apr 12.
Publication Year :
2023

Abstract

Competing Interests: X.S.X. and Y.C. are the inventors of the provisional patent applications for BD series neutralizing antibodies and are founders of Singlomics Biopharmaceuticals. All other authors declare no competing interests.

Details

Language :
English
ISSN :
2666-6065
Volume :
33
Database :
MEDLINE
Journal :
The Lancet regional health. Western Pacific
Publication Type :
Academic Journal
Accession number :
37069895
Full Text :
https://doi.org/10.1016/j.lanwpc.2023.100762